At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 68 enrolled
Drug / intervention
LY3502970 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multiple-Dose Study in Participants With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics,and Pharmacodynamics of LY3502970
In Brief
A Phase 1 clinical trial evaluating LY3502970 and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 68 participants across 6 sites in 2 countries.
Detailed Summary
The main purpose of this study is to learn more about the safety of LY3502970 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3502970 is in the bloodstream, how long it takes the body to eliminate it, and how it affects blood sugar. Participation could last up to 18 weeks and may include up to 14 visits (including three overnight stays) in the study center.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesGermany, United States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartOct 2020
Primary CompletionJul 2021
TodayJul 2026
First PostedJun 11, 2020
Enrollment StartOct 8, 2020
Primary CompletionJul 12, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.1 years ago
Interventions
LY3502970drug
Administered orally.
Placebodrug
Administered orally.